Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03430700
Title Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)
Acronym PROMPT
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University College, London
Age Groups: senior | adult
Covered Countries GBR

No variant requirements are available.